No abstract

Ovarian cancer is a common gynecological malignant tumor. Early diagnosis is important for the prognosis of patients with ovarian cancer. To evaluate the accuracy of the Copenhagen Index (CPH‐I) in detecting malignant adnexal tumors and to compare the diagnostic accuracy of CPH‐I and the Risk of Ovarian Malignancy Algorithm (ROMA). PubMed, Web of Science, and Cochrane Library databases were used to retrieve eligible studies. The overall sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the (summary receiver operating characteristic) curve (AUC) were 0.81, 0.88, 6.61, 0.22, 30.43, and 0.91, respectively, in diagnosing malignant adnexal tumors. In addition, using ROMA, the sensitivity, specificity, and AUC were 0.83, 0.85, and 0.90, respectively. CPH‐I showed high accuracy in diagnosing malignant adnexal tumors, which could be an alternative method with similar efficacy to ROMA. CPH‐I was more advantageous in diagnosing adnexal tumors in postmenopausal women.

The meta-analysis was prepared to evaluate the diagnostic value of surface-enhanced Raman spectroscopy for patients with breast cancer and to provide some statistically significant reference for the detection process. PubMed, Web of Science, Cochrane library, and Embase databases were retrieved for randomized clinical trials by two independent reviewers. A comprehensive search was performed on July 15, 2022. Meta-Disc 1.4 was used to calculate Spearman correlation coefficient. STATA 14.1 software was used to evaluate the diagnostic effect and the performance of subgroup analysis, which could be conducted to explore the potential sources of heterogeneity. Review manager 5.3 software was performed for quality assessment in our meta-analysis. The results displayed 19 studies with 1299 patients were included according to the inclusion and exclusion criteria. Meta-analysis displayed the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and the area under the curve of using surface enhanced Raman spectroscopy for diagnosing the patients with breast cancer were 0.91 (95% CI 0.85-0.94), 0.94 (95% CI 0.91-0.96), 14.06 (95% CI 9.25-21.35), 0.10 (95% CI 0.06-0.17), ), and 0.97 (95% CI 0.95-0.98), respectively. The source of specificity heterogeneity was from different sample volume mixed with nanoparticle. Surface-enhanced Raman spectroscopy had high sensitivity and specificity in the diagnosis of breast cancer. It was an accurate and effective technique for patients with breast cancer.